1
|
Zhang G, Hu F, Huang T, Ma X, Cheng Y, Liu X, Jiang W, Dong B, Fu C. The recent development, application, and future prospects of muscle atrophy animal models. MEDCOMM – FUTURE MEDICINE 2024; 3. [DOI: 10.1002/mef2.70008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/06/2024] [Accepted: 12/01/2024] [Indexed: 01/06/2025]
Abstract
AbstractMuscle atrophy, characterized by the loss of muscle mass and function, is a hallmark of sarcopenia and cachexia, frequently associated with aging, malignant tumors, chronic heart failure, and malnutrition. Moreover, it poses significant challenges to human health, leading to increased frailty, reduced quality of life, and heightened mortality risks. Despite extensive research on sarcopenia and cachexia, consensus in their assessment remains elusive, with inconsistent conclusions regarding their molecular mechanisms. Muscle atrophy models are crucial tools for advancing research in this field. Currently, animal models of muscle atrophy used for clinical and basic scientific studies are induced through various methods, including aging, genetic editing, nutritional modification, exercise, chronic wasting diseases, and drug administration. Muscle atrophy models also include in vitro and small organism models. Despite their value, each of these models has certain limitations. This review focuses on the limitations and diverse applications of muscle atrophy models to understand sarcopenia and cachexia, and encourage their rational use in future research, therefore deepening the understanding of underlying pathophysiological mechanisms, and ultimately advancing the exploration of therapeutic strategies for sarcopenia and cachexia.
Collapse
Affiliation(s)
- Gongchang Zhang
- Geriatric Health Care and Medical Research Center West China Hospital, Sichuan University Chengdu Sichuan Province China
- National Clinical Research Center for Geriatrics West China Hospital, Sichuan University Chengdu Sichuan Province China
| | - Fengjuan Hu
- Geriatric Health Care and Medical Research Center West China Hospital, Sichuan University Chengdu Sichuan Province China
- National Clinical Research Center for Geriatrics West China Hospital, Sichuan University Chengdu Sichuan Province China
| | - Tingting Huang
- National Clinical Research Center for Geriatrics West China Hospital, Sichuan University Chengdu Sichuan Province China
| | - Xiaoqing Ma
- Longkou People Hospital Longkou Shandong Province China
| | - Ying Cheng
- Geriatric Health Care and Medical Research Center West China Hospital, Sichuan University Chengdu Sichuan Province China
- National Clinical Research Center for Geriatrics West China Hospital, Sichuan University Chengdu Sichuan Province China
| | - Xiaolei Liu
- Geriatric Health Care and Medical Research Center West China Hospital, Sichuan University Chengdu Sichuan Province China
- National Clinical Research Center for Geriatrics West China Hospital, Sichuan University Chengdu Sichuan Province China
| | - Wenzhou Jiang
- Longkou People Hospital Longkou Shandong Province China
| | - Birong Dong
- Geriatric Health Care and Medical Research Center West China Hospital, Sichuan University Chengdu Sichuan Province China
- National Clinical Research Center for Geriatrics West China Hospital, Sichuan University Chengdu Sichuan Province China
| | - Chenying Fu
- Geriatric Health Care and Medical Research Center West China Hospital, Sichuan University Chengdu Sichuan Province China
- National Clinical Research Center for Geriatrics West China Hospital, Sichuan University Chengdu Sichuan Province China
- Department of Laboratory of Aging and Geriatric Medicine National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University Chengdu Sichuan Province China
| |
Collapse
|
2
|
Tepp K, Aid-Vanakova J, Puurand M, Timohhina N, Reinsalu L, Tein K, Plaas M, Shevchuk I, Terasmaa A, Kaambre T. Wolframin deficiency is accompanied with metabolic inflexibility in rat striated muscles. Biochem Biophys Rep 2022; 30:101250. [PMID: 35295995 PMCID: PMC8918847 DOI: 10.1016/j.bbrep.2022.101250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2021] [Revised: 02/28/2022] [Accepted: 03/08/2022] [Indexed: 11/26/2022] Open
Abstract
The protein wolframin is localized in the membrane of the endoplasmic reticulum (ER), influencing Ca2+ metabolism and ER interaction with mitochondria, but the exact role of the protein remains unclear. Mutations in Wfs1 gene cause autosomal recessive disorder Wolfram syndrome (WS). The first symptom of the WS is diabetes mellitus, so accurate diagnosis of the disease as WS is often delayed. In this study we aimed to characterize the role of the Wfs1 deficiency on bioenergetics of muscles. Alterations in the bioenergetic profiles of Wfs1-exon-5-knock-out (Wfs1KO) male rats in comparison with their wild-type male littermates were investigated using high-resolution respirometry, and enzyme activity measurements. The changes were followed in oxidative (cardiac and soleus) and glycolytic (rectus femoris and gastrocnemius) muscles. There were substrate-dependent alterations in the oxygen consumption rate in Wfs1KO rat muscles. In soleus muscle, decrease in respiration rate was significant in all the followed pathways. The relatively small alterations in muscle during development of WS, such as increased mitochondrial content and/or increase in the OxPhos-related enzymatic activity could be an adaptive response to changes in the metabolic environment. The significant decrease in the OxPhos capacity is substrate dependent indicating metabolic inflexibility when multiple substrates are available. Wolfram syndrome (WS) model rats have muscle type-dependent metabolic changes. Substrate-dependent modulation of OxPhos in WS model rat muscles. Metabolic inflexibility in early-stage WS rat muscle mitochondria.
Collapse
|
3
|
Crouzier L, Richard EM, Diez C, Alzaeem H, Denus M, Cubedo N, Delaunay T, Glendenning E, Baxendale S, Liévens JC, Whitfield TT, Maurice T, Delprat B. OUP accepted manuscript. Hum Mol Genet 2022; 31:2711-2727. [PMID: 35325133 PMCID: PMC9402244 DOI: 10.1093/hmg/ddac065] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2021] [Revised: 02/28/2022] [Accepted: 03/15/2022] [Indexed: 12/03/2022] Open
Abstract
Wolfram syndrome (WS) is a rare genetic disease characterized by diabetes, optic atrophy and deafness. Patients die at 35 years of age, mainly from respiratory failure or dysphagia. Unfortunately, there is no treatment to block the progression of symptoms and there is an urgent need for adequate research models. Here, we report on the phenotypical characterization of two loss-of-function zebrafish mutant lines: wfs1aC825X and wfs1bW493X. We observed that wfs1a deficiency altered the size of the ear and the retina of the fish. We also documented a decrease in the expression level of unfolded protein response (UPR) genes in basal condition and in stress condition, i.e. after tunicamycin treatment. Interestingly, both mutants lead to a decrease in their visual function measured behaviorally. These deficits were associated with a decrease in the expression level of UPR genes in basal and stress conditions. Interestingly, basal, ATP-linked and maximal mitochondrial respirations were transiently decreased in the wfs1b mutant. Taken together, these zebrafish lines highlight the critical role of wfs1a and wfs1b in UPR, mitochondrial function and visual physiology. These models will be useful tools to better understand the cellular function of Wfs1 and to develop novel therapeutic approaches for WS.
Collapse
Affiliation(s)
- Lucie Crouzier
- MMDN, Université Montpellier, EPHE, INSERM, Montpellier, France
| | | | - Camille Diez
- MMDN, Université Montpellier, EPHE, INSERM, Montpellier, France
| | - Hala Alzaeem
- MMDN, Université Montpellier, EPHE, INSERM, Montpellier, France
| | - Morgane Denus
- MMDN, Université Montpellier, EPHE, INSERM, Montpellier, France
| | - Nicolas Cubedo
- MMDN, Université Montpellier, EPHE, INSERM, Montpellier, France
| | | | - Emily Glendenning
- Development, Regeneration and Neurophysiology, School of Biosciences, University of Sheffield, Sheffield S10 2TN, UK
| | - Sarah Baxendale
- Development, Regeneration and Neurophysiology, School of Biosciences, University of Sheffield, Sheffield S10 2TN, UK
| | | | - Tanya T Whitfield
- Development, Regeneration and Neurophysiology, School of Biosciences, University of Sheffield, Sheffield S10 2TN, UK
| | - Tangui Maurice
- MMDN, Université Montpellier, EPHE, INSERM, Montpellier, France
| | - Benjamin Delprat
- To whom correspondence should be addressed: Tel: +33 467143623; Fax: +33 47149295;
| |
Collapse
|